AU2016306694B2 - Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases - Google Patents

Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases Download PDF

Info

Publication number
AU2016306694B2
AU2016306694B2 AU2016306694A AU2016306694A AU2016306694B2 AU 2016306694 B2 AU2016306694 B2 AU 2016306694B2 AU 2016306694 A AU2016306694 A AU 2016306694A AU 2016306694 A AU2016306694 A AU 2016306694A AU 2016306694 B2 AU2016306694 B2 AU 2016306694B2
Authority
AU
Australia
Prior art keywords
alkyl
optionally substituted
alkenyl
alkynyl
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016306694A
Other languages
English (en)
Other versions
AU2016306694A1 (en
Inventor
Emily H. Cheng
James Hsieh
Paul JENG
Ouathek Ouerfelli
Guangli Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2016306694A1 publication Critical patent/AU2016306694A1/en
Application granted granted Critical
Publication of AU2016306694B2 publication Critical patent/AU2016306694B2/en
Priority to AU2021203883A priority Critical patent/AU2021203883A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016306694A 2015-08-12 2016-08-12 Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases Ceased AU2016306694B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021203883A AU2021203883A1 (en) 2015-08-12 2021-06-11 Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562204385P 2015-08-12 2015-08-12
US62/204,385 2015-08-12
US201562253030P 2015-11-09 2015-11-09
US62/253,030 2015-11-09
PCT/US2016/046889 WO2017027841A1 (en) 2015-08-12 2016-08-12 Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021203883A Division AU2021203883A1 (en) 2015-08-12 2021-06-11 Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases

Publications (2)

Publication Number Publication Date
AU2016306694A1 AU2016306694A1 (en) 2018-01-18
AU2016306694B2 true AU2016306694B2 (en) 2021-03-11

Family

ID=56740558

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016306694A Ceased AU2016306694B2 (en) 2015-08-12 2016-08-12 Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
AU2021203883A Abandoned AU2021203883A1 (en) 2015-08-12 2021-06-11 Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021203883A Abandoned AU2021203883A1 (en) 2015-08-12 2021-06-11 Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases

Country Status (7)

Country Link
US (2) US10975051B2 (enExample)
EP (1) EP3334713B1 (enExample)
JP (1) JP2018529649A (enExample)
CN (1) CN108349924A (enExample)
AU (2) AU2016306694B2 (enExample)
CA (1) CA2990477A1 (enExample)
WO (2) WO2017027841A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2990477A1 (en) 2015-08-12 2017-02-16 Memorial Sloan-Kettering Cancer Center Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
US20180335421A1 (en) * 2015-11-20 2018-11-22 Memorial Sloan-Kettering Cancer Center Method for screening inhibitors targeting anti-apoptotic survival pathways
JP2019103077A (ja) * 2017-12-07 2019-06-24 Kddi株式会社 管理装置、管理方法、管理プログラム及び通信システム
CN111904958B (zh) * 2019-05-09 2022-09-13 浙江大学 Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US6570002B1 (en) 1999-02-26 2003-05-27 The Johns Hopkins University Inhibitor of programmed cell death
UY26942A1 (es) * 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
ATE474568T1 (de) 2001-05-30 2010-08-15 Univ Michigan Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs.
US7354928B2 (en) 2001-11-01 2008-04-08 The Regents Of The University Of Michigan Small molecule inhibitors targeted at Bcl-2
WO2005007878A2 (en) * 2003-07-22 2005-01-27 Dana-Farber Cancer Institute, Inc. Method of modulating apoptosis and compositions thereof
WO2008017123A1 (en) 2006-08-11 2008-02-14 The Walter And Eliza Hall Institute Of Medical Research Methods for modulating apoptosis in platelets
EP3549951A3 (en) * 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
BR112012005343A2 (pt) * 2009-09-10 2016-03-22 Novartis Ag sulfonamidas como inibidores de proteínas da família bcl-2 para o tratamento de câncer
US8501811B2 (en) * 2010-06-17 2013-08-06 Washington University TASPASE1 inhibitors and their uses
FR2962649B1 (fr) 2010-07-19 2025-10-24 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
JP5852658B2 (ja) 2010-09-24 2016-02-03 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン デユビキチナーゼ阻害剤およびその使用方法
US20140296223A1 (en) 2011-09-01 2014-10-02 The General Hospital Corporation Method for regulating skin pigmentation
US9744171B2 (en) * 2012-03-06 2017-08-29 Vanderbilt University Positive allosteric modulators for melanocortin receptors
US10093640B2 (en) 2012-09-21 2018-10-09 Vanderbilt University Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors
WO2014109696A1 (en) 2013-01-10 2014-07-17 Alf Grandien Method for immortalization of b cells and uses thereof
CA2990477A1 (en) * 2015-08-12 2017-02-16 Memorial Sloan-Kettering Cancer Center Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
US20180335421A1 (en) * 2015-11-20 2018-11-22 Memorial Sloan-Kettering Cancer Center Method for screening inhibitors targeting anti-apoptotic survival pathways

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AVDEENKO, A. P. ET AL., "Reactions of-arylsulfonylquinone imines with enamines", Russian Journal of Organic Chemistry, 2011, vol. 47 (8), pages 1169-1180& CAS Registry Number 1338060-25-5 *
CAS Registry Number 848315-71-9, 3-Benzofurancarboxylic acid, 2,6-dimethyl-5-[(phenylsulfonyl)amino]-, ethyl ester, STN Entry date 12 April 2005 *
CAS Registry Number 848334-49-6 *
CAS Registry Number 848334-54-3 *
CAS Registry Number 848334-57-6 *
CAS Registry Number 848335-86-4 *

Also Published As

Publication number Publication date
CN108349924A (zh) 2018-07-31
CA2990477A1 (en) 2017-02-16
AU2021203883A1 (en) 2021-07-08
US20180237407A1 (en) 2018-08-23
EP3334713B1 (en) 2021-07-21
US20180237406A1 (en) 2018-08-23
WO2017027841A1 (en) 2017-02-16
US11098021B2 (en) 2021-08-24
AU2016306694A1 (en) 2018-01-18
WO2017027845A1 (en) 2017-02-16
EP3334713A1 (en) 2018-06-20
US10975051B2 (en) 2021-04-13
JP2018529649A (ja) 2018-10-11

Similar Documents

Publication Publication Date Title
EP3544970B1 (en) Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
AU2020263390B2 (en) Degraders of cyclin-dependent kinase 12 (CDK12) and uses thereof
US10723753B2 (en) Ras inhibitors and uses thereof
US10711036B2 (en) MALT1 inhibitors and uses thereof
US11248007B2 (en) Inhibitors of MALT1 and uses thereof
AU2020362194B2 (en) A pyrazolopyrimidine derivative as a HCK inhibitor for use in therapy, in particular MYD88 mutated diseases
AU2020301399B2 (en) HCK degraders and uses thereof
AU2021203883A1 (en) Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
JP2019537599A (ja) Ｍａｌｔ１分解のための化合物
WO2016201374A1 (en) Sulfanide adenosine derivatives and uses thereof
WO2016077581A1 (en) Isosteviol triazoles and uses thereof
EP3371149A1 (en) Polyamine sulfonamides and uses thereof
EP4482825A2 (en) Inhibitors of ddr1 and ddr2 for the treatment of arthritis
US20200062776A1 (en) Hedgehog acyltransferase inhibitors and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired